<DOC>
	<DOCNO>NCT00558961</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose Gleevec combination Chlorambucil previously treat CLL patient .</brief_summary>
	<brief_title>Dose Escalation Study Gleevec Chlorambucil Previously Treated Chronic Lymphocytic Leukemia Patients</brief_title>
	<detailed_description>A recent study Aloyz et al demonstrate synergistic effect imatinib chlorambucil-mediated cytotoxicity CLL cell vitro . Imatinib inhibit c-abl sensitizes cell chlorambucil . The Phase I component study determine maximum tolerate dose recommended Phase II dose Gleevec use combination chlorambucil . Once maximum tolerate dose determine , total 16 patient enrol Phase II component study . This study determine dose limit toxicity , pharmacokinetics pharmacodynamics Gleevec combination chlorambucil .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Bcell chronic lymphocytic leukemia ( ) Rai stage 0II indication treatment NCI Working Group Criteria : ( b ) Rai stage III IV . Received minimum one prior chemotherapy regimen . Prior treatment corticosteroid , immunotherapy , monoclonal antibody radiation therapy permit . White blood cell count &gt; 25 x 10^9/L ECOG 0 , 1 , 2 . Adequate renal hepatic function Platelets &gt; 75 x 10^9/L , transfusion independent . Neutrophils &gt; 1.0 x 10^9/L , transfusion independent Documented prolymphocytic leukemia ( PLL ; prolymphocytes , 55 % blood ) Active cardiovascular disease define NYHA class IIIIV categorization . Intercurrent illness medical condition preclude safe administration ribavirin . Concurrent use chronic steroid , except replacement therapy adrenal insufficiency Known infection HIV , Hepatitis B C. Concurrent malignancy ( resect basal squamous cell skin cancer insitu carcinoma ) . Received previous therapy CLL within 28 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>CLL</keyword>
	<keyword>chronic lymphocytic leukemia</keyword>
	<keyword>leukemia</keyword>
	<keyword>gleevec</keyword>
	<keyword>chlorambucil</keyword>
</DOC>